What FDA and CDRH Staffing Pressures Mean for Medtech Startups
The regulatory environment for medical devices is becoming more constrained, and that is starting to affect how medtech startups interact with FDA. As workloads continue to rise inside CDRH, the practical result for sponsors is not just slower response times — it is a shift in the nature of engagement itself. More questions are being pushed into formal pathways, timelines are becoming less predictable, and even routine exchanges may now require more preparation and more lead time than they once did.
For startups, that shift matters because regulatory strategy is not built in a vacuum. It directly influences development timelines, clinical planning, fundraising milestones, and launch readiness. When the agency environment becomes less flexible, the margin for error narrows. Teams that once may have been able to rely on lighter-touch interactions are now having to think more carefully about how they structure each FDA touchpoint and how much internal resource they can realistically commit to regulatory work.
“We’re starting to see the operational strain at CDRH show up in very practical ways. In recent months, I’ve received FDA feedback at 11PM CT on the day it was due—something that was previously uncommon—and have seen more informal, flexible interactions shift toward more resource-intensive formal pathways like pre-submissions,” shares Syd Wiggins, Senior Regulatory Affairs Specialist at Avio. “In one case, a straightforward protocol review that would have been handled via email prior to the layoffs instead required a full pre-sub due to staffing limitations. Similarly, requests for expedited engagement, such as STeP sprint discussions, are being pushed into pre-submission timelines. These changes don’t just reflect workload pressure—they’re actively reshaping how sponsors need to plan for timelines, resources, and regulatory strategy.”
That perspective reflects a broader reality for startups: the FDA process is still navigable, but it now rewards proactive planning more than ever. Founders should assume that what used to be a quick clarification may now require a more formal submission strategy. They should also build more flexibility into development schedules, avoid overpromising on regulatory timing, and recognize that the cost of regulatory indecision is higher in this environment than it may have been before.
This is where Avio can help by providing targeted support to startups that need help interpreting the current landscape, preparing for FDA interactions and aligning regulatory planning with broader development goals. The work is not about replacing internal decision-making — it is about helping teams move through a more complex environment with better information and a clearer plan.
The bigger takeaway? Regulatory capacity is now part of the startup equation. Medtech companies that understand this early will be better positioned to adapt, preserve runway, and keep programs moving forward even as the external landscape changes.
Need help navigating the journey? We’re here.
